I+Med, an independent cooperative based in Álava, is to invest €20 million over three years for the development of the Biomedical Institute for Intelligent Nanohydrogels (IIBNI) within Álava Technology Park. It will be the first of its kind in the world, positioning i+Med in the medium and long term as a world leader in personalised medicine by means of artificial intelligence systems that are directly integrated into nanohydrogels.

The project will enable the company to increase its current staff of 71 people (58 are researchers, including 16 PhDs) to 125, at the start of the project forecast for late 2024, one hundred of whom will be top-level researchers.

Since its foundation in 2014, this cooperative of scientists has focused its activity on the development of personalised nanomedicine projects in the field of smart nanohydrogels for the controlled release of drugs and active substances, which allows the generation of more effective and direct drugs.

i+Med currently has nine medical devices of reference on the market and holds six technological patents. It is currently in the research phase for 18 new projects that will be launched soon, some during the transition to the new plant and most in 2024, coinciding with the inauguration of the Institute.

The realisation of this project, among others, serves to consolidate Alava’s position as an economic development hub of international reference in the Pharmaceutical and Biomedical fields.